{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 4,
    "verified": 2,
    "rejected": 2,
    "verification_rate": 0.5
  },
  "verified_evidence": [
    {
      "id": "comp_1",
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quad rival ent in activated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were collected from healthcare personnel (18-64 years) in 2018 19 (N = 723) and 2019 20 (N = 684) influenza seasons.",
      "supports_claim": true,
      "explanation": "The quote (with minor typographical differences) appears on page 1: 'In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quad rival ent in activated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were collected from healthcare personnel (18-64 years) in 2018 19 (N = 723) and 2019 20 (N = 684) influenza seasons.' The wording is nearly identical to the quote to verify, with only minor spacing and typographical differences.. The quote confirms that the randomized trial compared quadrivalent recombinant (RIV4, i.e., Flublok), quadrivalent egg-based (IIV4), and cell culture-based (ccIIV4) influenza vaccines. Further, the document specifies that the IIV4 group included Fluarix (see page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent; ccIIV4: Cell culture based IIV...'). Therefore, the quote and supporting context confirm that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine), directly supporting the claim.",
      "presence_explanation": "The quote (with minor typographical differences) appears on page 1: 'In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quad rival ent in activated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were collected from healthcare personnel (18-64 years) in 2018 19 (N = 723) and 2019 20 (N = 684) influenza seasons.' The wording is nearly identical to the quote to verify, with only minor spacing and typographical differences.",
      "support_explanation": "The quote confirms that the randomized trial compared quadrivalent recombinant (RIV4, i.e., Flublok), quadrivalent egg-based (IIV4), and cell culture-based (ccIIV4) influenza vaccines. Further, the document specifies that the IIV4 group included Fluarix (see page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent; ccIIV4: Cell culture based IIV...'). Therefore, the quote and supporting context confirm that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine), directly supporting the claim.",
      "original_relevance": "This quote describes the randomized trial design, explicitly stating that quadrivalent recombinant (RIV4, i.e., Flublok) and quadrivalent egg-based (IIV4, which includes Fluarix) vaccines were evaluated, supporting the claim that Flublok was evaluated against a standard-dose quadrivalent vaccine."
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "supports_claim": true,
      "explanation": "A very similar version of the quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The wording and numbers match the quote to verify, with only minor formatting and spacing differences.. The quote lists the vaccine allocation in the pivotal trial, showing that Flublok (RIV4, recombinant quadrivalent influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both used as comparators. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "A very similar version of the quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The wording and numbers match the quote to verify, with only minor formatting and spacing differences.",
      "support_explanation": "The quote lists the vaccine allocation in the pivotal trial, showing that Flublok (RIV4, recombinant quadrivalent influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both used as comparators. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote lists the vaccine allocation, showing that Fluarix (a standard-dose quadrivalent vaccine) and RIV4 (Flublok) were both used in the pivotal trial, directly supporting the claim."
    }
  ],
  "rejected_evidence": [
    {
      "id": "comp_3",
      "quote": "ccIIV4: Cell culture based IIV4 (Flu cel vax Quad rival ent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quad rival ent by SanofiPasteur, RIV4).",
      "reason": "does not support claim",
      "original_explanation": "This quote clarifies that RIV4 refers to Flublok Quadrivalent, confirming that Flublok was one of the vaccines evaluated in the trial."
    },
    {
      "id": "comp_4",
      "quote": "During Year 1, HCP were stratified by two age groups (18\u221244 years and 45\u221264 years) and randomized at 4 4 2 2",
      "reason": "does not support claim",
      "original_explanation": "This quote indicates that participants were randomized to different vaccine groups, supporting that a head-to-head comparison was performed in the pivotal trial."
    }
  ],
  "model_used": "gpt-4.1"
}